From Dr. Google to the Driverless Car: The Shift from Agency to Surrender

AI querying for health information isn’t entirely new. We’ve seen this with Dr. Google for years — patients typing symptoms into search engines, clicking through forums, and piecing together their own conclusions. At least back then, we were still in the driver’s seat: reading, analyzing, comparing sources, and ultimately deciding. It was messy, biased, and frequently wrong, but it remained our decision.

I’ve seen this pattern firsthand in the vitiligo community. Patients would spend hours cross-referencing scattered online information before reaching out to us or their doctors. They owned the process, flawed as it was.

Now, we’re moving to the back seat of a driverless car. A decade of algorithmic media has trained younger users to accept recommendation as the default mode of decision-making. Having spent years letting TikTok or Instagram choose their entertainment and opinions, it is only natural they now let ChatGPT or Grok choose their medicine. The AI doesn’t just surface options; it synthesizes, ranks, and often recommends with calm authority. The recommender system decides what circulates and survives — not the FDA label, not the glossy brochure, but whether the AI deems it relevant, trustworthy, and aligned with the user’s expressed (or inferred) preferences.

As I documented in “How AI Is Replacing Social Media — and What It Means for Healthcare Communications,” social platforms optimized for outrage and endless scrolling; AI optimizes for you. It remembers your past questions, your skin type, your insurance status, your tolerance for needles or daily creams.

Gen Z and Millennials already begin many health journeys on TikTok and Instagram. The logical next stop is the AI companion that feels more empathetic and tireless than most doctors.

Vitiligo’s Double-Onset Peak Creates a Marketing Schism

Vitiligo illustrates this divide perfectly. The condition has two onset peaks: one around age 20 and another around age 50. The 50-year-old patient still seeks the physician’s authority and the clinical brochure — traditional agency.

But the 20-year-old entering the first peak brings a lifetime of algorithmic grooming to the table. They don’t want to “research”; they want to yield to a system that already knows them.

Two Threats: Cognitive Dependence and Commercial Capture

Here the risks split into two distinct but connected threats.

• First is cognitive dependence: patients outsourcing judgment to fluent systems that do too much thinking for them. Many users are no longer just using AI as a tool. They’re letting it narrow the field, frame the trade-offs, and sometimes make the choice feel half-made already.
• Second is commercial capture: brands rushing to shape what the AI retrieves, ranks, and ultimately says. This creates a fierce new competitive battleground for pharma. Traditional SEO is no longer enough when the moment of decision is increasingly mediated by AI systems. 

In my recent piece, “What Real People Say About Opzelura on Reddit and the Raw Truth About Treating Vitiligo,” I showed how raw, unfiltered patient experiences already dominate these conversations. When AI systems pull from such sources without strong grounding in verified evidence, the risk of distorted recommendations grows significantly.

If your clinical data isn’t in the engine’s retrieval pipeline, the AI will simply hallucinate an answer based on whoever shouted the loudest on Reddit.

Brands must now optimize for training data, retrieval-augmented generation pipelines, and agentic workflows. This means publishing clean, structured datasets and working with trusted clinical and patient organizations to ensure evidence surfaces ethically when patients query. Without strong governance, these incentives can easily drift away from durable patient outcomes toward whatever maximizes clicks, conversions, or short-term prescriptions.

The Hidden Cost: Confident Misinformation in High-Stakes Decisions

I’ve seen this pattern before in vitiligo: patients chasing unproven “cures” because an algorithm amplified the loudest voices. Scaling that to pharmaceutical choices risks exactly the proxy-optimization trap I highlighted in “Building a Responsible AI-Powered Ecosystem in Vitiligo.”

The danger is confident misinformation. If a patient surrenders to a model that fluently explains why a snake oil is actually safe and effective, the result isn’t just bad marketing — it’s a sentinel event, a signal of complete system failure in patient safety. We paused Vitiligo.AI as a mental health assistant when we realized the actual misguidance rate hit well above 5%.

The Wharton study showed people readily abdicate reasoning when AI is fluent and frictionless. For the younger cohort, that 73% surrender rate likely skews even higher. Friction — whether a slow website or a complex PDF — is now a signal of obsolescence. If the pharma brand isn’t fluently integrated into their AI companion, that brand is effectively invisible to the very demographic that will be managing this condition for the next sixty years.

AI will optimize whatever target it is given — click-throughs, conversion to prescription, or actual durable outcomes. Without deliberate design, it will chase the former.

A Responsible Path: Build the Ecosystem, Don’t Just Advertise Into It

The Vitiligo Research Foundation has chosen the harder road: systemic integration over flashy pilots. We insist AI must serve patient-centered outcomes — stable repigmentation, continuity of care, reduced burden — not just faster enrollment or prettier dashboards.

Pharmaceutical partners who want to reach the AI-native generation must play by a higher standard:

• Let patient-facing AI be reviewed independently and be fully transparent about where and how it fails.
• Create true two-way value: patients get clarity and support, while the system learns from real-world use and generates better evidence.
• Judge success by patient understanding, persistence, and long-term outcomes — not just by how efficiently queries turn into prescriptions.
• Treat AI oversight with the same seriousness as clinical trials and post-marketing surveillance.

Otherwise we risk industrializing the very fragmentation and fatigue we are trying to solve.

The Adult Conclusion

It is time for the industry to face the demographic math. We cannot keep using supposedly “universal” tactics designed for 50-year-old patients to reach a 20-year-old cohort shaped by algorithms from childhood.

That mismatch becomes even harder to defend in a country where roughly 43 million adults have low literacy skills and many patients simply do not have the time, patience, or reading ability to decode dense pharma messaging.

For younger patients, the moment of truth is no longer in the waiting room or on a Google results page. It lives inside the logic of an AI companion. Ignore that, and the problem is no longer just bad marketing. It is an abandonment of the next generation of patients.

The Choice: Participate or Vanish

My conversations with industry leaders and legislators last week have confirmed one thing: we are at a point of no return.

The challenge ahead is no longer technical — it is ethical. We are the stewards of the information that will shape the next sixty years of a young patient’s life. If we allow “commercial capture” to dictate the logic of AI companions, we industrialize patient fatigue.

The AI-powered “Black Box” is training itself right now, with or without your clinical data. If you choose to keep your evidence behind proprietary walls, you are effectively choosing to be invisible to the AI-native generation.

The Vitiligo Research Foundation is already facilitating the “Trainable Dialogue” I’ve described with a wealth of structured information we have put online.

Yet on the market scale, it requires a departure from the infantile marketing of the past. We must jointly harness the power of behavioral nudges to create bidirectional value for both industry and patients. To do otherwise isn’t just a loss of market share — it is a dereliction of our duty to the next generation of patients.

 The shift has already begun. The real question is whether the industry will embrace this new paradigm before the next vitiligo therapies come to market — or scramble to catch up after the fact.

by Yan Valle

Prof. h.c., CEO VR Foundation 

Note: This is an opinion piece for public discussion and should not be treated as medical or marketing advice. For serious health decisions, consult qualified professionals. Data and studies referenced are current as of April 2026.